Betadine® products prove 99.99% effective against COVID-19

Three Betadine® products, known and used in many homes, hospitals, and dental clinics across South Africa, have proven effective against the novel coronavirus (SARS-CoV-2) that causes COVID-19.

The products tested include Betadine® Mouthwash and Gargle, Betadine®Surgical Scrub, and Betadine® Antiseptic Solution. Laboratory testing conducted at the Duke-NUS Medical School in Singapore showed strong in-vitro virucidal activity, killing 99.99% of the SARS-CoV-2 virus in 30 seconds1, and in the Tropical Infectious Diseases Research and Education Center (TIDREC) study at the University of Malaysia9, direct evidence was presented of the virucidal activity of Betadine® Mouthwash & Gargle and against SARS-CoV-2 in just 15 seconds.

Mundipharma, the distributor of Betadine® products, announced these results after the TIDREC research9 was accepted by the British Dental Journal (BDJ) and published as a Letter on 26 June 2020, and the Duke-NUS research was published in the respected Infectious Disease and Therapy Journal on 08 July 20201.

Betadine® products contain povidone-iodine (PVP-I), which has been widely used throughout the world as an antiseptic since the middle of last century. Shannon te Roller, General Manager of Mundipharma South Africa, says, “Betadine® products with PVP-I have been well accepted in South Africa for home use and by the medical community for decades, with benefits that include no reported antimicrobial resistance, fast-acting, a long-lasting effect, and extremely low allergenicity on skin 3.”

The TIDREC research concludes that the broad-spectrum antimicrobial and rapid virucidal activity of PVP-I products against SARS-CoV-2 suggests its importance in infection control. It goes on to note that, as an additional protective barrier to PPE, these products may reduce disease transmission. PVP-I is easily administered and has been used in both hospital and community settings for more than 55 years* and can thus be readily integrated into existing infection control protocols. PVP-I based products can be used as part of infection control measures during the COVID-19 pandemic and can augment health and hygiene measures to reduce the spread of COVID-191.

Up-to-the-minute scientific research7,8,9 backs up the use and efficacy of Betadine® against the novel coronavirus, and across the world in a variety of medical disciplines including orthopaedic surgery10, dentistry and dental surgery, and ENT surgery 11, 12 13. The use of PVP-I has been recommended in protocols in response to the COVID-19 pandemic. In SA, the South African Dental Association (SADA), recommends its use during patient treatment and pre-operatively, stating that, to this end, the most important method for reducing the viable bacterial and viral load is through pre-procedural rinsing with PVP-I (0.23% to 1%) or 1% hydrogen peroxide rinse2.

Betadine® Mouthwash and Gargle is recommended for use for infections of mouth and throat at full strength, or as a mouthwash, diluted one part with two parts of water; Betadine® Surgical Scrub is used for disinfecting hands in the medical and dental profession; and Betadine® Antiseptic Ointment is used to effectively stop bacteria, fungi, and viruses from infecting injuries caused by minor daily accidents.

Past studies have also shown that PVP-I has the broadest antimicrobial activity of available antiseptics and has been used to combat the spread of infection against a wide range of viruses, including highly pathogenic and low pathogenic influenza viruses (H1N1, H3N2, H1N2, H5N3, H7N7, and HpN2), and SARS and MERS coronaviruses. In all instances, rapid virucidal activity has been demonstrated with both Betadine® Mouthwash and Gargle and Betadine®Surgical Scrub3,4,5,6.

For more information, please visit www.mundipharma.co.za/

About Mundipharma

Mundipharma South Africa is a prime example of an organization that consistently delivers high-quality healthcare products while standing by the values it represents. Its mission is to alleviate the suffering of patients and to substantially improve their quality of life. Mundipharma South Africa is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, ophthalmology, and consumer healthcare.

About BETADINE®

BETADINE®, the flagship brand of Mundipharma and its range of povidone-iodine and non povidone-iodine products, has been trusted by hospitals and consumers worldwide. For more than 60 years, Betadine products are used to prevent and treat various conditions, from the upper respiratory tract infections, epidemics, and wound infections to personal, feminine, and hand hygiene.

In-vitro and clinical studies have demonstrated that BETADINE® povidone-iodine kills a broad range of bacteria, viruses, and fungi, including antibiotic-resistant strains.

®: BETADINE is a Registered Trademark

 S0 BETADINE® Mouthwash & Gargle. Contains povidone-iodine 1 % w/v. Contains ethanol. Registration No. C/16.4/142. S0 BETADINE® Surgical Scrub. Contains povidone-iodine 7,5 % w/v. Reference No. G1571 (Act 101/1965). S0  Betadine® Antiseptic Solution. Contains povidone-iodine 10 % w/v. Reference No. G1570 (Act 101/1965). S0 Betadine® Antiseptic Ointment. Contains povidone-iodine 10 % w/w. Reference No. G1574 (Act 101/1965). Please refer to the package inserts for full prescribing information. 

 

Please report any suspected adverse events to ZAdrugsafety@ mundipharma.co.za. Mundipharma (Pty) Ltd, Block D, Grosvenor Square, Park Lane, Century City, Cape Town, South Africa, 7441. www.mundipharma.co.za.

ZA-M-BET-0820-0005.

REFERENCES

1. Anderson DE, Sivalingam V, Kang AEZ, et al. Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease. Infect Dis Ther. 2020. https://doi.org/10.1007/s40121-020-00316-3.

2. The South African Dental Association. SADA Dental Protocol in Response to the Covid-19 Pandemic. 2020.

3. Lachapelle J-M, Castel O, Fueyo Casado A, et al. Antiseptics in the era of bacterial resistance with – focus on povidone iodine. Clin Pract 2013;10(5):579-59.

4. Eggers M, Eickamnn M, Zorn J. Rapid and Effective Virucidal Activity of Povidone-Iodine Products Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA). Infect Dis Ther 2015;4:491 -501.

5. Eggers M, Eickman M, Zorn J. Can oral disinfection with povidone iodine prevent viral respiratory infections? Poster ASN226 IMRP Singapore 2015.

6. Kanagalingam J, Feliciano R, Hah JH, et al. Practical use of povidone-iodine antiseptic in the maintenance of oral health and in the prevention and treatment of common oropharyngeal infections. Int J Clin Pract 2015;69(11):1247-1256.

7. Mady LJ, Kubik MW, Baddour K, et al. Oral Oncology (2020); in Press https://doi.org/10.1016/j.oraloncology.2020.104724.

8. Ather A, Patel B, Ruparelet NB et al. Journal of Endodontics 46(5): in press https:// www.aae.org/specialty/clinical-resources/coronavirus-disease-19-covid-19-implications-for-clinical-dental-care/.

9. P. Hassandarvish, V. Tiong, A. B. Sazaly, Malaya, Malaysia; N. A. Mohamed, Kuala Lumpur, Malaysia; H. Arumugam, A. Ananthanarayanan, M. Qasuri, Y. Hadjiat, Singapore (2020); in Press https://doi.org/10.1038/s41415-020-1794-1

10. Emanuel C et al. Prevention of Infection and Disruption of the Pathogen Transfer Chain in Elective Surgery. The Journal of Arthroplasty 2020: 35: S28-S31.https://www.ncbi.nlm.nih.gov/research/coronavirus/publication/32389410

11. Bidra AS et al. Rapid In-Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Using Povidone-Iodine Oral Antiseptic Rinse. Journal of Prosthodontics 2020. https://www.ncbi.nlm.nih.gov/research/coronavirus/publication/32511851

12. Challacombe SJ et al. Povidone Iodine. 2020;228(9):656‐657. doi:10.1038/s41415-020-1589-4 https://pubmed.ncbi.nlm.nih.gov/32385428

13. Kham M et al. Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic. American Journal of Otolaryngology. 2020: 41: 5: 102618. https://www.ncbi.nlm.nih.gov/research/coronavirus/publication/32574894

*Mundipharma data on file, 2020.